Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Katharina Leucht"'
Autor:
Marc-Oliver Grimm, Katharina Leucht
Publikováno v:
European Urology Open Science, Vol 33, Iss , Pp 81-82 (2021)
Externí odkaz:
https://doaj.org/article/38a0d8bb38684639b09ae4744bea3390
Autor:
Marc-Oliver Grimm, Christine Barbara Grün, Günter Niegisch, Martin Pichler, Florian Roghmann, Bernd Schmitz-Dräger, Gustavo Baretton, Marc Schmitz, Christian Bolenz, Susan Foller, Katharina Leucht, Ulrike Schumacher, Martin Schostak, Johannes Meran, Wolfgang Loidl, Friedemann Zengerling
Publikováno v:
The Lancet Oncology. 24:347-359
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35589fb422fc92766cf0d5e01270983c
https://doi.org/10.1016/s1470-2045(23)00053-0
https://doi.org/10.1016/s1470-2045(23)00053-0
Autor:
Anne Tabea, Theurich, Lutz, Leistritz, Katharina, Leucht, Tobias, Franiel, Ulf, Teichgräber, Susan, Foller, Marc-Oliver, Grimm
Publikováno v:
European Urology Focus. 8:1323-1330
Prostate artery embolization (PAE) is an increasingly used minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic obstruction (BPO) OBJECTIVE: To analyze the impact of PAE on voiding and storage symptoms.Between J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a330f0f46ef996f5bd6adb35147d99fb
https://doi.org/10.1016/j.euf.2022.01.011
https://doi.org/10.1016/j.euf.2022.01.011
Autor:
Laura Schomburg, Amer Malouhi, Marc-Oliver Grimm, Maja Ingwersen, Susan Foller, Katharina Leucht, Ulf Teichgräber
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:2003-2012
Purpose Therapy decision for patients with metastatic renal cell carcinoma (mRCC) is highly dependent on disease monitoring based on radiological reports. The purpose of the study was to compare non-standardized, common practice free text reporting (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2744057ca83576e51144bc5e28174d
https://doi.org/10.1007/s00432-022-03997-0
https://doi.org/10.1007/s00432-022-03997-0
Publikováno v:
Der Onkologe. 28:167-178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e6edb85512a21dbad3c00e14520f7b5
https://doi.org/10.1007/s00761-021-01062-y
https://doi.org/10.1007/s00761-021-01062-y
Publikováno v:
best practice onkologie. 16:603-611
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b800531ba297e661483ab1f24e9b212b
https://doi.org/10.1007/s11654-021-00345-5
https://doi.org/10.1007/s11654-021-00345-5
Publikováno v:
Der Urologe. 60:1400-1408
BACKGROUND Intravesical instillation of bacillus Calmette-Guerin (BCG) is an accepted strategy to reduce the risk of recurrence and possibly progression of high-risk non-muscle invasive bladder cancer (NMIBC). However, side effects are not uncommon.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70af5ca4972aea4ed4727dbf320c580b
https://doi.org/10.1007/s00120-021-01681-8
https://doi.org/10.1007/s00120-021-01681-8
Publikováno v:
Im Fokus Onkologie. 24:44-53
Beim muskelinvasiven, nichtmetastasierten Urothelkarzinom der Harnblase ist die radikale Zystektomie der Therapiestandard. Trotz kurativer Intention liegt die 5‑Jahres-Uberlebensrate nur bei etwa 50 %. Eine cisplatinbasierte (neo-)adjuvante Chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab4b216572a005d7462d5f78ee41a1ad
https://doi.org/10.1007/s15015-021-3531-2
https://doi.org/10.1007/s15015-021-3531-2
Publikováno v:
Der Urologe. 60:803-815
Immun-Checkpoint-Inhibitoren (ICI) werden heute routinemasig u. a. zur Behandlung von fortgeschrittenen oder metastasierten Urothel- und Nierenzellkarzinomen eingesetzt. Daruber hinaus untersuchen derzeit mehrere Studien ihre Rolle im adjuvanten bzw.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eedc5bde48d302dda7e2ed279e234610
https://doi.org/10.1007/s00120-021-01550-4
https://doi.org/10.1007/s00120-021-01550-4
Publikováno v:
Cancers. 14(18)
Immune checkpoint inhibitors (ICI) are now, among other cancers, routinely used for the treatment of advanced or metastatic renal cell carcinoma (mRCC). In mRCC various combinations of ICIs and inhibitors of the vascular epidermal growth factor recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226bfb82db8ea11f3d807d3740ade71c
https://pubmed.ncbi.nlm.nih.gov/36139530
https://pubmed.ncbi.nlm.nih.gov/36139530